Compare Indonesia Energy Corporation Limited (INDO) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Mesoblast Limited — how do they compare? Indonesia Energy Corporation Limited trades at $2.85 (market cap $43.24M), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Mesoblast Limited is far larger — about 40.5× Indonesia Energy Corporation Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 116,953). Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and Mesoblast Limited for 14 Days on average.
| INDO | MESO | |
|---|---|---|
Market Cap | $43.24M | $1.75B |
Volume | 116,953 | 239,027 |
Sector | Energy | Health |
52-Week High | $6.74 | $20.96 |
52-Week Low | $2.49 | $13.19 |
Typical Hold Time | 24 Days | 14 Days |
Enterprise Value | $38.18M | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.77, unchanged on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $5.10 million in 2025 on revenue of $2.01 million, reflecting negative profit margins and cash flow from operations. Recent news highlights operational progress, including oil discovery at the K-29 well and participation in investment conferences.
Despite a 100% buy rating from 3 analysts, INDO faces significant financial challenges with negative profitability and cash burn. Investment potential hinges on successful execution of drilling operations to boost revenue, but risks include sustained losses, high valuation multiples relative to sales, and reliance on financing activities.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
